Citadel Advisors
IMMX icon

Citadel Advisors’s Immix Biopharma IMMX Stock Holding History

Citadel Advisors’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
+31,600
New +$293K ﹤0.01% 10947
2025
Q1 		– Sell
-11,500
Closed -$25.3K – 14990
2024
Q4 		$25.3K Buy
11,500
+2,600
+29% +$4.75K ﹤0.01% 13021
2024
Q3 		$13.3K Buy
+8,900
New +$17.9K ﹤0.01% 13068

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's IMMX Position: Q2 2026 in Review

Citadel Advisors increased its Immix Biopharma (IMMX) stake by 973% in Q2 2026, buying an estimated $4.26M and bringing the position to 506,157 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #4642.

Citadel Advisors first reported a position in IMMX in Q4 2021 and has held it in 6 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Citadel Advisors held 506,157 shares of Immix Biopharma worth $5.22M as of Q2 2026.
  • Citadel Advisors bought 458,984 Immix Biopharma shares in Q2 2026, an estimated $4.26M.
  • Immix Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4642 holding.
  • Citadel Advisors first reported a position in Immix Biopharma in Q4 2021 and has held it in 6 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.